Skip to content
10-Q

Quarterly Report

Adamas Pharmaceuticals, Inc.

0001328143-21-000042

← back to feed
Filed
May 10, 2021 12:00 AM ET
Period of report
—

On SEC.gov

Filing index ↗

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2021 · Apr 30, 2021 45.41M sh
Operating Cash Flow Q1 2021 · Mar 31, 2021 −$21.06M
Operating Cash Flow Q1 2021 · Mar 31, 2020 −$17.31M
Long Term Debt Q1 2021 · Mar 31, 2021 $126.16M
Long Term Debt Q1 2021 · Dec 31, 2020 $126.31M
Short Term Debt Q1 2021 · Mar 31, 2021 $3.58M
Short Term Debt Q1 2021 · Dec 31, 2020 $3.66M
Short Term Investments Q1 2021 · Mar 31, 2021 $0
Short Term Investments Q1 2021 · Dec 31, 2020 $11.71M
Cash And Equivalents Q1 2021 · Mar 31, 2021 $124.83M
Cash And Equivalents Q1 2021 · Dec 31, 2020 $71.66M
Stockholders Equity Q1 2021 · Mar 31, 2021 $5.94M
Stockholders Equity Q1 2021 · Dec 31, 2020 −$49.98M
Stockholders Equity Q1 2021 · Mar 31, 2020 −$15.85M
Stockholders Equity Q1 2021 · Dec 31, 2019 −$893K
Current Liabilities Q1 2021 · Mar 31, 2021 $29.18M
Current Liabilities Q1 2021 · Dec 31, 2020 $34.87M
Total Liabilities Q1 2021 · Mar 31, 2021 $163.31M
Total Liabilities Q1 2021 · Dec 31, 2020 $170.01M
Current Assets Q1 2021 · Mar 31, 2021 $158.1M
Current Assets Q1 2021 · Dec 31, 2020 $111.74M
Total Assets Q1 2021 · Mar 31, 2021 $169.25M
Total Assets Q1 2021 · Dec 31, 2020 $120.03M
Sga Expense Q1 2021 · Mar 31, 2021 $26.64M
Sga Expense Q1 2021 · Mar 31, 2020 $24.55M
Rd Expense Q1 2021 · Mar 31, 2021 $1.81M
Rd Expense Q1 2021 · Mar 31, 2020 $2.47M
Net Income Q1 2021 · Mar 31, 2021 −$12.57M
Net Income Q1 2021 · Mar 31, 2020 −$16.65M
Operating Income Q1 2021 · Mar 31, 2021 −$9.53M
Operating Income Q1 2021 · Mar 31, 2020 −$13.11M
Cost Of Revenue Q1 2021 · Mar 31, 2021 $385K
Cost Of Revenue Q1 2021 · Mar 31, 2020 $572K
Revenue Q1 2021 · Mar 31, 2021 $19.31M
Revenue Q1 2021 · Mar 31, 2020 $14.48M